Subtype-specific dependencies and therapeutic opportunities in small cell lung cancer - PubMed
7 hours ago
- #Therapeutic vulnerabilities
- #Small cell lung cancer
- #Epigenetic therapy
- Small cell lung cancer (SCLC) accounts for ~15% of lung cancers and is aggressive with rapid proliferation, early metastasis, and poor prognosis.
- Current therapies like platinum-based chemotherapy and immune checkpoint inhibitors offer modest survival benefits due to frequent relapse and resistance.
- SCLC is characterized by the loss of tumor suppressor genes TP53 and RB1 and exhibits molecular heterogeneity driven by master transcription factors.
- Distinct molecular subtypes in SCLC have unique gene expression programs and therapeutic vulnerabilities, leading to cell plasticity and subtype switching under treatment pressure.
- Understanding subtype-specific dependencies and epigenetic mechanisms is crucial for developing durable and effective therapies for SCLC.
- The review highlights the potential of epigenetic-targeted strategies in treating SCLC.